U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206693) titled 'Impact of PSA-based Screening on Mortality Among Men Aged 75-79: Target Trial Emulation' on Sept. 26.
Brief Summary: Opportunistic prostate-specific antigen (PSA) testing is widespread among men aged 75-79. Current American and European guidelines recommend PSA-based screening through shared decision-making if men are expected to live at least 10 more years-a threshold previously tied to ages 70-74. With rising life expectancy, Swedish men aged 75-79 now exceed this benchmark, averaging over 10 years.
Since no randomized controlled trials have examined screening in this age group, this study will use data from the Stockholm Prostate...